stockrow
Friday 6 November 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
- EPS
- −11.3%
- Free cash flow
- −39.1%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
18.06
0.70
+4.03%
Follow DYN
Alert me
Dyne Therapeutics, Inc. (DYN) Total debt
Dyne Therapeutics, Inc.'s total debt at the end of fiscal 2025 was $148.9M, up 475.6% from $25.9M in fiscal 2022. At the end of the quarter to 30 June 2026 it was $213.5M. Dyne Therapeutics, Inc. ranks 56th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $148.9M | 475.58% |
| FY2022 | $25.9M | (9.99%) |
| FY2021 | $28.7M | 751.64% |
| FY2018 | $3.4M | — |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $213.5M | 37.20% |
| Mar 2026 | $155.6M | 4.48% |
| Dec 2025 | $148.9M | 50.20% |
| Sep 2025 | $99.1M | 0.34% |
| 13 more quarters | Free account |
Total debt against peers
| Company | Total debt |
|---|---|
| CELC Celcuity, Inc. compare | $753.2M |
| TLX Telix Pharmaceuticals Limited compare | $575.9M |
| VKTX Viking Therapeutics, Inc. compare | $250.7M |
| VRDN Viridian Therapeutics, Inc. compare | $242.2M |
| DYN Dyne Therapeutics, Inc. | $213.5M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $72.9M |
| ACAD ACADIA Pharmaceuticals Inc. compare | $48.1M |
| DNLI Denali Therapeutics Inc. compare | $5.4M |
| ELVN Enliven Therapeutics, Inc. compare | $445.0K |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt